Aclarion, Inc. — News

Aclarion, Inc. (ACON) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $2.75 per share a year ago.

zacks.com - 2026-08-06 13:01:28

PR Audio: BROOMFIELD, Colo., August 04, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

prismmediawire.com - 2026-08-04 07:05:36

Partnership brings Nociscan for chronic low back pain to one of the nation's leading neurosurgery and spine care networks Goodman Campbell Brain & Spine is recognized nationally for its role in neurosurgery training and clinical research Availability of Nociscan in Indiana reflects Company's focus on expansion and adding to its growing base of provider sites across the country BROOMFIELD, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology.

globenewswire.com - 2026-08-04 07:00:00

PR Audio: Broomfield, CO, July 29, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

prismmediawire.com - 2026-07-29 07:03:10

141% year-over-year scan volume growth in first half of 2026 Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA Healthcare to secure insurance coverage for Nociscan in the U.S. Continued progress toward the CLARITY trial readout with the addition of multiple new trial sites Strengthened intellectual property position with the addition of a new AI focused patent bringing total issued and pending patents to 65 worldwide Strong balance sheet with $16.3M cash and no debt as of June 30, 2026 BROOMFIELD, Colo., July 29, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the company's recent momentum and value creating priorities through the first half of 2026.

globenewswire.com - 2026-07-29 07:00:00

PR Audio: BROOMFIELD, Colo., July 21, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

prismmediawire.com - 2026-07-21 07:04:29

Abstracts presented at American Society of Pain & Neuroscience (ASPN) annual meeting across surgical decision support and basivertebral nerve ablation Early findings from real-world evidence study demonstrate immense utility and ability of Nociscan to be incorporated into clinical practice Case study represents first reported use of Nociscan to guide basivertebral nerve ablation in a patient without classic Modic changes on standard MRI, resulting in 95% relief of long-standing chronic low back pain BROOMFIELD, Colo., July 21, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the presentation of two abstracts featuring Nociscan® at the American Society of Pain & Neuroscience (ASPN) Annual Meeting in Miami, Florida.

globenewswire.com - 2026-07-21 07:00:00

PR Audio: BROOMFIELD, Colo., July 07, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

prismmediawire.com - 2026-07-07 07:01:47

Texas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understanding the exact source of a patient's pain before recommending treatment CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., July 07, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced Texas Spine Care Center as a new clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial.

globenewswire.com - 2026-07-07 07:00:00

BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that it will be presenting at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on Wednesday, June 17, 2026 at 8:30 AM PT at the Bellagio Resort & Hotel.

globenewswire.com - 2026-06-10 07:00:00

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain.

prismmediawire.com - 2026-06-09 07:00:49

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers BROOMFIELD, Colo.

globenewswire.com - 2026-06-09 07:00:00

PR Audio: BROOMFIELD, Colo., June 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.

prismmediawire.com - 2026-06-08 07:06:08

BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. , (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today issued the following statement in response to a recent communication issued by Echo Lake Capital and its principal, Ephraim Fields.

globenewswire.com - 2026-06-08 07:05:00

BROOMFIELD, Colo., June 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its stockholders approved all proposals at its 2026 Annual Meeting of Stockholders held on June 4, 2026.

prismmediawire.com - 2026-06-08 07:02:29

BROOMFIELD, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its stockholders approved all proposals at its 2026 Annual Meeting of Stockholders held on June 4, 2026.

globenewswire.com - 2026-06-08 07:00:00

Broomfield, CO, June 3, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, announced today it has established an agreement with the Institute of Neuro Innovation (INI), an industry-leading clinic in Los Angeles focused on research, innovation, and applied neuroscience.

prismmediawire.com - 2026-06-03 06:00:07

Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group Adds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan with bone metabolic information from SPECT-CT  Supports scalable growth strategy while building data assets critical to payer and provider adoption BROOMFIELD, Colo., June 03, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, announced today it has established an agreement with the Institute of Neuro Innovation (INI), an industry-leading clinic in Los Angeles focused on research, innovation, and applied neuroscience.

globenewswire.com - 2026-06-03 06:00:00

Award-winning, NIH funded study indicates that immune-associated biological signatures may play a role in some cases of back pain.

prismmediawire.com - 2026-06-01 06:04:53

Award-winning, NIH funded study indicates that immune-associated biological signatures may play a role in some cases of back pain Nociscan's underlying MRS technology enabled measurement of intradiscal propionic acid to uncover immune-linked patient subtypes Latest findings point to potential clinical applications of Nociscan beyond surgical decision support, expanding the future scope of precision spine care BROOMFIELD, Colo., June 01, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its Nociscan® magnetic resonance spectroscopy (MRS) technology was used in a new research study exploring the biological factors associated with back pain in patients with Modic type 1 (MC1) changes, a condition marked by inflammation near the spinal disc.

globenewswire.com - 2026-06-01 06:00:00

BROOMFIELD, Colo., May 28, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today issued the following statement in response to the press release issued by Echo Lake Capital and its offer to acquire the Company for $4.00 per share in cash and contingent value rights:

prismmediawire.com - 2026-05-28 15:04:37

BROOMFIELD, Colo., May 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today issued the following statement in response to the press release issued by Echo Lake Capital and its offer to acquire the Company for $4.00 per share in cash and contingent value rights: Aclarion's Board of Directors and management team are committed to acting in the best interests of the Company and all of its shareholders.

globenewswire.com - 2026-05-28 14:49:00

Offers $4.00 per share in cash plus CVR Stock currently trades below the value of its cash and other assets Believes company's public shell worth at least another $6 million if Board effected a reverse takeover Stock price down 99% since its IPO only four years ago Board owns few shares so lacks financial incentive to maximize shareholder value Directors have been paid $5.6 million or 50% of company's current equity market value Thramann has overseen destruction of shareholder value at Aclarion and Auddia Inc. with both stocks down 99% since their IPOs "Independent" Director Deitsch has been sued for violating securities law and has longstanding relationship with Thramann Believes certain directors have violated federal securities laws and ACON's Code of Business Conduct for, among other things, failing to publicly disclose large personal IRS tax liens NEW YORK, NY / ACCESS Newswire / May 28, 2026 / Earlier today Ephraim Fields of Echo Lake Capital sent a letter to the Board of Directors of Aclarion Inc. (NASDAQ:ACON). The letter criticized the directors' performance, compensation and qualifications and noted the tremendous destruction of shareholder value that has occurred.

accessnewswire.com - 2026-05-28 08:00:00

Aclarion (ACON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

zacks.com - 2026-05-19 13:01:15

Aclarion, Inc. (ACON) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.55. This compares to a loss of $9.32 per share a year ago.

zacks.com - 2026-05-13 19:11:09

BROOMFIELD, Colo., May 07, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of Lanman Spinal Neurosurgery as a clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial.

prismmediawire.com - 2026-05-11 16:51:43